Enveric Biosciences announced the discovery of multiple, promising novel compounds sourced using the company?s Psybrary? platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI?). The novel compounds span seven distinct molecule classes totaling at least 57 unique product opportunities, all of which are protected by Enveric?s expansive intellectual property portfolio and represent potential out-licensing opportunities and non-dilutive revenue streams for the Company.

Together, the novel and distinct molecule classes broaden and deepen Enveric?s library of assets targeting difficult-to-address mental health disorders, adding to its lead candidate EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next generation synthetic prodrug of the active metabolite, psilocin. The novel compounds span seven diverse molecule classes and subclasses, including: Novel Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors (SNDRI); Non-selective Serotonin Reuptake Inhibitor (NSRI); Novel MDMA Derivatives (EMD) Series; Bifunctional Psilocin Prodrugs (BPP); Novel Psilocin Prodrug (NPP) Series; Melatonin-Receptor Agonist (MRA) Series; Neuroplastogenic Antidepressant (NAD-01).